Genmab A/S
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Genmab A/S develops differentiated antibody therapeutics targeting cancer and other serious diseases using proprietary platforms including DuoBody, HexaBody, UniBody and HuMab-Mouse technologies; core products encompass approved medicines such as EPKINLY (epcoritamab, a CD3xCD20 bispecific T-cell engager for relapsed/refractory diffuse large B-cell lymphoma marketed with AbbVie), TIVDAK (tisotumab vedotin, a tissue factor-directed antibody-drug conjugate for recurrent/metastatic cervical cancer marketed with Seagen), royalties from partner-marketed DARZALEX (daratumumab for multiple myeloma and AL amyloidosis by Janssen), Kesimpta (ofatumumab for relapsing remitting multiple sclerosis by Novartis), RYBREVANT (amivantamab for non-small cell lung cancer by Janssen), TECVAYLI and TALVEY (teclistamab and talquetamab bispecifics for relapsed/refractory multiple myeloma by Janssen) and TEPEZZA (teprotumumab for thyroid eye disease by Horizon); the company advances a broad pipeline of proprietary and partnered bispecific antibodies, antibody-drug conjugates and immune checkpoint modulators in oncology and autoimmune indications. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab operates globally through subsidiaries in the Netherlands, United States, Japan, Germany and China, serving pharmaceutical partners and patients across North America, Europe and Asia Pacific. Recent developments include the 2024 acquisition of ProfoundBio for $1.8 billion to bolster its antibody-drug conjugate capabilities (with subsequent discontinuation of certain assets), the September 2025 announcement of an $8 billion acquisition of Merus to integrate petosemtamab (a late-stage bispecific for head and neck cancer) and accelerate transition to a wholly owned model, successful independent launches and international expansions of EPKINLY and TIVDAK in Europe and Japan, and positive Phase III data for epcoritamab expansions plus Rina-S programs driving projected double-digit revenue growth to $3.5-3.7 billion in 2025.
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Major Shareholder Announcement
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab Announces Financial Results for the First Quarter of 2026